Vimpat (UCB) filed with FDA as monotherapy for Epilepsy
UCB has filed a supplemental new drug application for Vimpat (lacosamide) as monotherapy in the treatment of partial-onset seizures in patients with Epilepsy aged 17 years and older. In the US, Vimpat is already approved as adjunctive therapy for the treatment of partial-onset seizures in patients with epilepsy aged 17 years and older.
Investigational data from the Phase III lacosamide conversion to monotherapy study in adults with partial-onset seizures that support the US filing will be presented by leading clinical researchers at the Annual Meeting of the American Epilepsy Society in December. Lacosamide is not currently approved as monotherapy.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.